Riociguat: First global approval

Drugs

Volumn 73, Issue 17, 2013, Pages 1967-1975

  Conole, Daniel ^a   Scott, Lesley J ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIOCIGUAT;

ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; DRUG APPROVAL; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PULMONARY EMBOLISM; PYRAZOLES; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84892592536     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0149-5     Document Type: Article

References (39)

1. Agarwal R, Gomberg-Maitland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J. 2011;162(2):201-13.
2. Archer SL. Riociguat for pulmonary hypertension: a glass half full. N Engl J Med. 2013;369(4):386-8.
3. Delcroix M. Chronic post-embolic pulmonary hypertension: a new target for medical therapies? Eur Respir Rev. 2013;22(129):258-64.
4. Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123-34.
5. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev. 2009;18(111):35-41.
6. Boerrigter G, Burnett JC. Soluble guanylate cyclase: not a dull enzyme. Circulation. 2009;119(21):2752-4.
7. Bayer Inc. Product monograph: ADEMPAS riociguat (film-coated) tablet; 2013. http://www.bayer.ca/?q=en/node/62 (Accessed 7 Oct 2013).
8. Bayer Inc. Bayer receives approval for Adempas as first drug to treat rare heart and lung disease; 2013. http://www.bayer.com (Accessed 7 Oct 2013).
9. US Food and Drug Administration. FDA approves Adempas to treat pulmonary hypertension; 2013. http://www.fda.gov/news events/newsroom/pressannouncements/ ucm370866.htm (Accessed 29 Oct 2013).
10. Bayer HealthCare Pharmaceuticals Inc. Adempas (riociguat) tablets, for oral use: US prescribing information; 2013. http://labeling.bayerhealthcare.com/ html/products/pi/Adempas-PI.pdf (Accessed 29 Oct 2013).
11. Bayer HealthCare. Bayer's riociguat for patients with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension submitted for regulatory approval in the U.S. and EU; 2013. http://www.bayer.com (Accessed 7 Oct 2013).
12. Bayer Inc. Bayer submits investigational drug riociguat for patients with chronic thromboembolic pulmonary hypertension for regulatory approval in Japan; 2013. http://www.bayerpharma. com (Accessed 7 Oct 2013).
13. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29.
14. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40.
15. Bayer. BAY63-2521: long-term extension study in patients with chronic thromboembolic pulmonary hypertension (CHEST-2) [ClinicalTrials.gov identifier NCT009110429]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov (Accessed 8 Oct 2013).
16. Bayer. BAY63-2521: long-term extension study in patients with pulmonary arterial hypertension (PATENT-2) [ClinicalTrials.gov identifier NCT00863681]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www. clinicaltrials.gov (Accessed 10 Oct 2013).
17. Bayer Healthcare Pharmaceuticals Inc. Briefing document for Cardiovascular and Renal Drugs Advisory Committee: riociguat (BAY 63-2521); 2013. http://www.fda.gov/downloads/advisory committees/ committeesmeetingmaterials/drugs/cardiovascularandre naldrugsadvisorycommittee/ ucm363543.pdf (Accessed 8 Oct 2013).
18. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem. 2009;4(5):853-65.
19. Frey R, Muck W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guan-ylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol. 2008;48:926-34.
20. Becker EM, Stasch J-P, Bechem M, et al. Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension. PLoS ONE. 2013;8(8):e73502.
21. Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS ONE. 2012;7(8):e43433.
22. Evgenov OV, Zou L, Zhang M, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis [abstract]. BMC Pharmacol. 2011;11(Suppl 1):O9.
23. Becker EM, Stasch JP, Bechem M, et al. Comparison of different vasodilators, endothelin antagonist, PDE5 inhibitior and sGC stimulators, in an animal model of secondary pulmonary hypertension: effects on "desaturation" [abstract]. BMC Pharmacol. 2011;11(Suppl 1):P5.
24. Kojonazarov B, Lang M, Weissmann N, et al. Effects of riociguat on pulmonary vascular remodeling in severe experimental pulmonary hypertension [abstract]. Am J Respir Crit Care Med. 2011;183(Suppl):A2516.
25. Pichl A, Parajuli N, Seimetz M, et al. Stimulation of soluble guanylate cyclase by riociguat prevents tobacco smoke-induced pulmonary hypertension in mice [abstract]. Pneumologie. 2012;66(6):A310.
26. Sharkovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hy-pertens. 2010;28(8):1666-75.
27. Ott IM, Alter ML, von Websky K, et al. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS ONE. 2012;7(8):e42623.
28. Geschka S, Kretschmer A, Sharkovska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS ONE. 2011;6(7):e21853.
29. Frey R, Muck W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol. 2011;51(7):1051-60.
30. Frey R, Muck W, Unger S, et al. No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin [abstract]. BMC Pharmacol. 2011;11(Suppl 1):P25.
31. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010;36(4):792-9.
32. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long-term safety, tolerability and efficacy [abstract]. Am J Resp Crit Care Med. 2012;185:A2370.
33. Bayer HealthCare. Interim results from CHEST-2 study support benefits of Bayer's Riociguat as demonstrated in Phase III CHEST-1 study; 2013. http://www.news.bayer.com (Accessed 27 Sep 2013).
34. Rubin LJ, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): a phase III long-term extension study (PATENT-2) [abstract]. Am J Resp Crit Care Med. 2013;187:A3531.
35. Galie N, Neuser D, Muller K, et al. A placebo-controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS) [abstract]. Am J Resp Crit Care Med. 2013;187(Suppl):A3530.
36. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013;41(4):853-60.
37. Ghio S, Bonderman D, Felix SB, et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. Eur J Heart Fail. 2012;14(8):946-53.
38. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, doseranging hemodynamic study. Circulation. 2013;128(5):502-11.
39. Bayer. Riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) (EAS) [ClinicalTrials.gov identifier NCT01784562]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www. clinicaltrials.gov (Accessed 8 Oct 2013).